Follow Us TR

News Details

RedHill Biopharma Submits COVID-19 Clinical Trial Application for Phase 2/3 Study with Opaganib

About Redhill Biopharma Ltd.
  • NASDAQ: $RDHL
  • Notified: $7.05
  • 07:01 EDT

Price Chart